NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

CVKD

Cadrenal Therapeutics Inc

Jul 11 • 04:00PM ET

12.92

Dollar change -0.08
Percentage change -0.62	%

Healthcare • Biotechnology • USA • NASD

Peers: ABBV JNJ MRK PFE LLY AMGN BMY REGN GILD VRTX

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-9.25	Insider Own	32.37%	Shs Outstand	1.91M	Perf Week	-0.46%
Market Cap	25.41M	Forward P/E	-	EPS next Y	-4.55	Insider Trans	0.00%	Shs Float	1.33M	Perf Month	-13.87%
Enterprise Value	18.07M	PEG	-	EPS next Q	-1.77	Inst Own	3.53%	Short Float	1.50%	Perf Quarter	-13.87%
Income	-12.83M	P/S	-	EPS this Y	18.84%	Inst Trans	49.15%	Short Ratio	0.75	Perf Half Y	-27.58%
Sales	0.00M	P/B	4.04	EPS next Y	35.78%	ROA	-171.09%	Short Interest	0.02M	Perf YTD	-10.84%
Book/sh	3.20	P/C	3.46	EPS next 5Y	12.39%	ROE	-208.59%	52W High	22.90 -43.58%	Perf Year	87.21%
Cash/sh	3.73	P/FCF	-	EPS past 3/5Y	-0.45% -	ROIC	-209.93%	52W Low	5.70 126.67%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.18% 8.81%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-72.86%	Oper. Margin	-	ATR (14)	1.07	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.31	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	49.30	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.31	EPS Q/Q	-33.80%	SMA20	3.85%	Beta	0.98	Target Price	38.50
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-7.47%	Rel Volume	1.00	Prev Close	13.00
Employees	4	LT Debt/Eq	0.00	Earnings	May 08 BMO	SMA200	-17.42%	Avg Volume	26.68K	Price	12.92
IPO	Jan 20, 2023	Option/Short	No / Yes	EPS/Sales Surpr.	2.79% -	Trades		Volume	26,631	Change	-0.62%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-18-23	Initiated	Noble Capital Markets	Outperform	$4

Jun-12-25 08:00AM	Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients (Business Wire)
Jun-04-25 08:00AM	Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025 (Business Wire) +13.15%
May-15-25 07:30AM	Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness (Business Wire) +7.07%
May-08-25 08:00AM	Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update (Business Wire)
Apr-17-25 09:40AM	Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq (Business Wire)
08:00AM	Loading…
Apr-03-25 08:00AM	Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences (Business Wire)
Mar-13-25 04:05PM	Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin (Business Wire) +9.40%
Mar-05-25 07:28AM	Cadrenal and Abbott sign agreement for LVAD trial of tecarfarin (Medical Device Network)
Mar-04-25 08:00AM	Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3 LVAD (Business Wire)
Feb-06-25 09:00AM	Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin (Business Wire)
Feb-05-25 09:00AM	Cadrenal Therapeutics to Present at BIO CEO & Investor Conference (Business Wire)
Jan-09-25 08:44AM	Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 (Business Wire)
Dec-31-24 08:00AM	Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications (Business Wire)
Dec-18-24 09:00AM	Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings (Business Wire) +13.19%
Nov-19-24 09:00AM	Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook (PR Newswire) -7.29%
09:00AM	Loading…
Nov-12-24 09:00AM	CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS (PR Newswire)
Nov-07-24 09:00AM	CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE (PR Newswire)
Nov-01-24 08:00PM	Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds (PR Newswire) -18.86%
Oct-24-24 09:00AM	Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility (PR Newswire) +17.97%
Oct-23-24 09:00AM	CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM (PR Newswire)
Sep-23-24 04:15PM	Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference (PR Newswire) -12.17% +16.94%
Sep-11-24 01:00PM	Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing (ACCESSWIRE) +17.85%
Aug-22-24 09:00AM	Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients (PR Newswire) -5.52%
Aug-21-24 07:00AM	Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now (GlobeNewswire)
Aug-20-24 09:00AM	Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients (PR Newswire) +19.12%
07:00AM	Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now (GlobeNewswire)
Aug-14-24 09:00AM	Cadrenal Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
Aug-12-24 05:07PM	Cadrenal Therapeutics, Inc. (CVKD): A New Penny Stock to Buy Now (Insider Monkey) +13.67%
Aug-07-24 11:53PM	CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q2 2024 (InvestorPlace)
04:05PM	Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update (PR Newswire)
09:00AM	Loading…
Aug-06-24 09:00AM	Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs (PR Newswire)
Jul-17-24 09:00AM	Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024 (PR Newswire)
07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire)
Jul-16-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now (GlobeNewswire)
Jun-12-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now (GlobeNewswire)
Jun-11-24 04:15PM	Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024 (PR Newswire) +6.34%
07:00AM	Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now (GlobeNewswire)
Jun-03-24 09:00AM	Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients (PR Newswire) +5.45%
May-23-24 09:00AM	Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 (PR Newswire)
May-09-24 01:53PM	CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
09:00AM	Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update (PR Newswire)
Apr-11-24 04:30PM	Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024 (PR Newswire) -5.34%
Apr-09-24 09:00AM	Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts (PR Newswire) -19.86%
Mar-11-24 09:00AM	Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update (PR Newswire)
Feb-26-24 09:00AM	Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference (PR Newswire)
Feb-08-24 09:00AM	Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial (PR Newswire) -19.47%
Jan-31-24 09:00AM	Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions (PR Newswire) +8.33%
Jan-24-24 09:00AM	Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 (PR Newswire) +19.25%
Jan-04-24 09:00AM	Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference (PR Newswire)
Dec-19-23 09:00AM	Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target (PR Newswire) +6.94%
Dec-12-23 09:00AM	Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization (PR Newswire)
Nov-30-23 04:15PM	Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023 (PR Newswire) +8.70%
Nov-09-23 09:00AM	Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update (PR Newswire) -5.38%
Oct-16-23 08:38AM	Innovation Takes Center Stage: Florida's Life Sciences Leaders Shine at BioFlorida Conference (PR Newswire)
Oct-09-23 04:15PM	Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor Conference (PR Newswire)
Sep-05-23 08:00AM	Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology Congress (PR Newswire)
Aug-30-23 08:00AM	Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS) (PR Newswire)
Aug-28-23 04:15PM	Cadrenal Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-10-23 09:00AM	Cadrenal Therapeutics Provides Second Quarter 2023 Corporate Update (PR Newswire)
Aug-01-23 09:00AM	Cadrenal Therapeutics Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart Diseases (PR Newswire)
Jul-24-23 09:00AM	Cadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of Directors (PR Newswire) -11.65%
Jul-14-23 03:02PM	Cadrenal Therapeutics Announces Closing of $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules (PR Newswire) -18.37%
Jul-12-23 03:17PM	Cadrenal Therapeutics Announces $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules (PR Newswire) +29.31%
Jun-28-23 06:23AM	The 3 Hottest IPOs to Buy Before They Soar (InvestorPlace)
Jun-01-23 09:00AM	Cadrenal Therapeutics to Participate in the 2023 BIO International Convention in Boston (PR Newswire)
May-10-23 09:00AM	Cadrenal Therapeutics Provides First Quarter 2023 Corporate Update (PR Newswire)
May-09-23 04:30PM	Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2023 Investor Conference (PR Newswire)
Mar-30-23 09:00AM	Cadrenal Therapeutics Provides Fiscal Year 2022 Corporate Update (PR Newswire) +8.53%
Mar-09-23 09:00AM	Cadrenal Therapeutics Recognizes National Kidney Month with Goal to Advance Tecarfarin for Severely Underserved Patient Population (PR Newswire) -7.69%
Feb-08-23 09:00AM	Cadrenal Therapeutics to Ring the NASDAQ Stock Market Closing Bell on February 8, 2023 (PR Newswire) -9.26%
Feb-06-23 09:00AM	Cadrenal Therapeutics to Participate in the 2023 BIO CEO & Investor Conference (PR Newswire) -6.25%
Feb-01-23 09:00AM	Cadrenal Therapeutics Announces Formation of Scientific Advisory Board (PR Newswire)
Jan-24-23 02:11PM	Cadrenal Therapeutics (Nasdaq: CVKD) Announces Closing of Initial Public Offering (PR Newswire) -18.37%
Jan-23-23 11:39AM	What's Going On With Cadrenal Therapeutics Stock Today (Benzinga)
08:30AM	Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial Fibrillation (PR Newswire)
Jan-20-23 09:31AM	Cadrenal Therapeutics Announces Pricing of Initial Public Offering (IPO) (PR Newswire)

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CVKD

Cadrenal Therapeutics Inc

Upgrade your FINVIZ experience